New Method for Transcytosis Pathway and Ligand Discovery

转胞吞途径和配体发现的新方法

• 批准号: 6484192
• 负责人: WILLIAM J DOWER
• 金额: $ 14.49万
• 依托单位: XENOPORT, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至 2002-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6484192
• 关键词: bacterial virus; chemical registry /resource; combinatorial chemistry; drug delivery systems; drug discovery /isolation; folate; gastrointestinal drug absorption; genetic library; ligands; method development; oral administration; transcytosis

DESCRIPTION (provided by applicant): Current methods for oral delivery of macromolecular and other drugs poorly absorbed by the intestine do not provide adequate oral bio-availability. Thus, new intestinal pathways to transport larger quantities of compound must be identified. Unfortunately, current methods of pathway identification are inadequate. XenoPort will address this problem by developing a new method for displaying synthetic molecules on phage particles to fully exploit the exquisite sensitivity and versatility of the phage for display of molecular libraries. These libraries then will be used to screen for ligands to receptors directing the most active transcytosis pathways through the intestinal epithelium, enabling development of a commercial-ready technology platform adaptable to a wide variety of compounds in all therapeutic areas. Phase I studies will demonstrate feasibility by synthesizing, characterizing, and attaching a 1000-member chemical library to phage, and selecting for active compounds. Phase II will develop a highly diverse, 100,000-member library that also will be validated by selection of biologically active, synthetic molecules. The technology will be commercialized via internal product development and strategic partnerships. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（由申请人提供）：目前口服递送的方法